Zobrazeno 31 - 40
of 642
pro vyhledávání: '"Michael Kreuter"'
Autor:
Michael Kreuter, Francesco Del Galdo, Corinna Miede, Dinesh Khanna, Wim A. Wuyts, Laura K. Hummers, Margarida Alves, Nils Schoof, Christian Stock, Yannick Allanore
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-9 (2022)
Abstract Background Interstitial lung disease (ILD) is a common organ manifestation in systemic sclerosis (SSc) and is the leading cause of death in patients with SSc. A decline in forced vital capacity (FVC) is an indicator of ILD progression and is
Externí odkaz:
https://doaj.org/article/e3fd2be9ced043d2a49ee2bfb4b9b0f7
Autor:
Pavo Marijic, Larissa Schwarzkopf, Lars Schwettmann, Thomas Ruhnke, Franziska Trudzinski, Michael Kreuter
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither evidence from prospective data nor a guideline recommendation, whic
Externí odkaz:
https://doaj.org/article/4e34ba0ccea946fd9f3c51ce2aa114a2
Autor:
Phillen Nozibuyiso Maqhuzu, Michael Kreuter, Thomas Bahmer, Nicolas Kahn, Martin Claussen, Rolf Holle, Larissa Schwarzkopf
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-9 (2021)
Abstract Introduction Treatments of interstitial lung diseases (ILDs) mainly focus on disease stabilization and relief of symptoms by managing inflammation or suppressing fibrosis by (in part costly) drugs. To highlight economic burden of drug treatm
Externí odkaz:
https://doaj.org/article/cd89b853370b41a0bdc3b3a4f6a214db
Autor:
Toby M. Maher, Elisabeth Bendstrup, Louis Dron, Jonathan Langley, Gerald Smith, Javaria Mona Khalid, Haridarshan Patel, Michael Kreuter
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear. Methods A targeted literature sear
Externí odkaz:
https://doaj.org/article/9047a9952448486e8bc024ece12972e8
Autor:
Maria Molina-Molina, Michael Kreuter, Vincent Cottin, Tamera J. Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M. Maher
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent Phase 2 study (NCT03099187) described a significant effect of pirfenidone vs. placebo on
Externí odkaz:
https://doaj.org/article/ee6f556226ca452ba20b217abf867f7c
Autor:
Theodoros Karampitsakos, Sebastiano Torrisi, Katerina Antoniou, Effrosyni Manali, Ioanna Korbila, Ourania Papaioannou, Fotios Sampsonas, Matthaios Katsaras, Eirini Vasarmidi, Despoina Papakosta, Kalliopi Domvri, Eva Fouka, Ioannis Organtzis, Zoe Daniil, Ilias Dimeas, Paraskevi Kirgou, Konstantinos I. Gourgoulianis, Ilias C. Papanikolaou, Katerina Markopoulou, Georgia Kounti, Eirini Tsapakidou, Efthymia Papadopoulou, Konstantinos Tatsis, Athena Gogali, Konstantinos Kostikas, Vasilios Tzilas, Serafeim Chrysikos, Spyridon Papiris, Demosthenes Bouros, Michael Kreuter, Argyrios Tzouvelekis
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Idiopathic Pulmonary Fibrosis (IPF) represents a chronic lung disease with unpredictable course. Methods We aimed to investigate prognostic performance of complete blood count parameters in IPF. Treatment-naïve patients with IPF
Externí odkaz:
https://doaj.org/article/58797cb815d347e8ac59a2f2cb5280c4
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-16 (2021)
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly subjects, and epidemiological studies suggest that th
Externí odkaz:
https://doaj.org/article/90da5345f2b14547b7f71dc9266c7200
Autor:
Tiago M. Alfaro, Marlies S. Wijsenbeek, Pippa Powell, Daiana Stolz, John R. Hurst, Michael Kreuter, Catharina C. Moor
Publikováno v:
Respiratory Research, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract People with rare lung diseases often suffer the burden of delayed diagnosis, limited treatment options, and difficulties in finding expert physicians. One of the reasons for the delay in diagnosis is the limited training for healthcare pract
Externí odkaz:
https://doaj.org/article/2a7051b77377434a8afc937ad1ac6574
Autor:
Marlies Wijsenbeek, Maria Molina-Molina, Olivier Chassany, John Fox, Liam Galvin, Klaus Geissler, Katherine M. Hammitt, Michael Kreuter, Teng Moua, Emily C. O'Brien, Ashley F. Slagle, Anna Krasnow, Matthew Reaney, Michael Baldwin, Natalia Male, Klaus B. Rohr, Jeff Swigris, Katerina Antoniou
Publikováno v:
ERJ Open Research, Vol 8, Iss 2 (2022)
Background An understanding of the experience of patients with progressive fibrosing interstitial lung disease (PF-ILD) is needed to select appropriate patient-reported outcome measures (PROMs) to evaluate treatment effect in clinical trials. Methods
Externí odkaz:
https://doaj.org/article/2b4d0656e26e4705841c755f6e5ab14a
Autor:
Sabina A. Guler, Sara Cuevas-Ocaña, Mouhamad Nasser, Wim A. Wuyts, Marlies S. Wijsenbeek, Antoine Froidure, Elena Bargagli, Elisabetta A. Renzoni, Marcel Veltkamp, Paolo Spagnolo, Hilario Nunes, Cormac McCarthy, Maria Molina-Molina, Francesco Bonella, Venerino Poletti, Michael Kreuter, Katerina M. Antoniou, Catharina C. Moor
Publikováno v:
ERJ Open Research, Vol 8, Iss 2 (2022)
This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translation
Externí odkaz:
https://doaj.org/article/97ffef864afb4f02a510fe5068eacd6b